August 25th, 2024 2:46 am
WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET.
See the original post:
Repligen Corporation to Present at Wells Fargo Healthcare Conference
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:46 am
VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it has engaged Syneos Health as the contract research organization (“CRO”) for its upcoming Phase II study exploring leronlimab and its effects on chronic inflammation.
Follow this link:
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:46 am
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today an interview with its CEO, Dr. Gary S. Jacob will air on The RedChip Small Stocks, Big Money™ show on Bloomberg TV, this Saturday, August 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Read the original post:
OKYO Pharma CEO Interview to Air on Bloomberg TV
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:46 am
Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its Norwegian partner Pharma Nordic AS (“Pharma Nordic”) to extend the territory covered by their exclusive distribution agreement for Bentrio® to Sweden and Denmark. Following the successful launch in Norway earlier this year, Pharma Nordic intends to introduce the Bentrio nasal spray for the prevention and treatment of allergic rhinitis in these two additional Scandinavian countries next year.
Visit link:
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:46 am
Experienced Communications Leader to Drive Growth and Educational Initiatives Experienced Communications Leader to Drive Growth and Educational Initiatives
Follow this link:
Wendy Vlieks Appointed as President of The Genome Partnership, Succeeding Leisa Zigman
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:46 am
GRANTS, NEW MEXICO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use.
See the rest here:
BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY...
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:46 am
BOSTON, Aug. 23, 2024 (GLOBE NEWSWIRE) -- eLabNext, an Eppendorf Group Company offering a flexible Digital Laboratory Platform equipped with a Laboratory Inventory Management System (LIMS) and Electronic Lab Notebook (ELN), announced today that its platform is now able to integrate with the Thermo Scientific™ VisionMate™ HSX High Speed Barcode Reader. The free VisionMate™ HSX High Speed Barcode Reader application is available through eLabNext’s library of add-ons, the eLabMarketplace, allowing users to expand the capabilities of their digital lab platform and streamline their laboratory operations.
Visit link:
Thermo Scientific™ VisionMate™ HSX High Speed Barcode Reader Integrates with eLabNext Platform
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:46 am
NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering").
See the article here:
Eyenovia Announces Closing of Public Offering
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:45 am
Participation in the events in Boston and New York highlights the Company's prominence in regenerative medicine and exosome technology Participation in the events in Boston and New York highlights the Company's prominence in regenerative medicine and exosome technology
Read more here:
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:45 am
SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel
Read more from the original source:
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:45 am
WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA’s common stock at a ratio of 1-for-12. ARCA’s common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol “ORKA” following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the “Merger”), with a new CUSIP number 687604108 and ISIN number US6876041087.
Read more:
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:45 am
This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance sheet for Cash and cash equivalents as of December 31, 2023 as $3,595,101, not $95,101 as previously stated. The full text of the corrected release is as follows:
More:
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:45 am
BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that, because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). Nasdaq has informed the Company that it has until October 21, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq approves the Company’s plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the Form 10-Q (or until February 17, 2025) to regain compliance.
More here:
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
August 25th, 2024 2:45 am
Read More...
Tags:
♫ Posted in Arthritis | | Comments Off»
August 25th, 2024 2:45 am
Read More...
Tags:
♫ Posted in Arthritis | | Comments Off»
August 25th, 2024 2:45 am
Read More...
Tags:
♫ Posted in Arthritis | | Comments Off»
August 25th, 2024 2:45 am
Read More...
Tags:
♫ Posted in Arthritis | | Comments Off»
August 25th, 2024 2:45 am
Read More...
Tags:
♫ Posted in Arthritis | | Comments Off»
August 25th, 2024 2:45 am
Read More...
Tags:
♫ Posted in Arthritis | | Comments Off»